Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation antigen (BCMA) receptor. It received accelerated approval in 2022 for patients ...

A Lingua Franca reader wrote in recently asking that we investigate the growing use of multiple in news stories where many would do just as nicely. Our editor had also noticed a trend toward the ...